Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 3, 2026, 6:41 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 1,699 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Infusion Clear all
Completed Not applicable Interventional

Local Anesthetic Infiltration and Infusion for Pain Control After Hip Replacement

NCT01409278
View directory record Official record
Conditions
Osteoarthritis
Interventions
Ropivacaine infiltration and saline infusion., Ropivacaine infiltration and infusion., Normal Saline
Procedure
Lead sponsor
Trinity Health Of New England
Other
Eligibility
18 Years to 80 Years
Enrollment
105 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
Hartford, Connecticut
Source: ClinicalTrials.gov public record
Updated Aug 3, 2011 · Synced Sep 3, 2026, 6:41 AM EDT
Completed Phase 3 Interventional Results available

Single-Arm Study To Evaluate The Efficacy and Safety of Valoctocogene Roxaparvovec in Hemophilia A Patients at a Dose of 4E13 vg/kg

NCT03392974
View directory record Official record
Conditions
Hemophilia A
Interventions
Valoctocogene Roxaparvovec
Biological
Lead sponsor
BioMarin Pharmaceutical
Industry
Eligibility
18 Years and older · Male only
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 2, 2023 · Synced Sep 3, 2026, 6:41 AM EDT
Terminated Early Phase 1 Interventional

Multimodal Pain Management Following Primary TKA

NCT02369523
View directory record Official record
Conditions
Pain
Interventions
Exparel, Ropivacaine cocktail (PIC), Bupivacaine
Drug
Lead sponsor
University of Utah
Other
Eligibility
40 Years to 90 Years
Enrollment
84 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Aug 14, 2023 · Synced Sep 3, 2026, 6:41 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

A Randomized Trial to Prevent Congenital Cytomegalovirus (CMV)

NCT01376778
View directory record Official record
Conditions
Congenital Cytomegalovirus Infection, Maternal Cytomegalovirus Infection
Interventions
CMV hyperimmune globulin, Placebo
Drug · Other
Lead sponsor
The George Washington University Biostatistics Center
Other
Eligibility
Female only
Enrollment
399 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2021
U.S. locations
16
States / cities
Birmingham, Alabama • Stanford, California • Aurora, Colorado + 13 more
Source: ClinicalTrials.gov public record
Updated Feb 1, 2023 · Synced Sep 3, 2026, 6:41 AM EDT
Not listed Phase 2 Interventional Results available

Ph2 NK Cell Enriched DCIs w/wo RLR9 Agonist, DUK-CPG-001 From Donors Following Allogeneic SCT

NCT02452697
View directory record Official record
Conditions
Myeloid Malignancies, Lymphoid Malignancies
Interventions
NK Cell enriched-DLI only, NK-DLI + DUK-CPG-001
Biological
Lead sponsor
Cristina Gasparetto
Other
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2024
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Feb 19, 2024 · Synced Sep 3, 2026, 6:41 AM EDT
Completed Phase 1 Interventional

A Phase 1, Open-Label, Dose-Escalation & Expanded Cohort, Continuous IV Infusion, Multi-center Study of the Safety, Tolerability,PK & PD of EPZ-5676 in Treatment Relapsed/Refractory Patients With Leukemias Involving

NCT01684150
View directory record Official record
Conditions
Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Myelodysplastic Syndrome, Myeloproliferative Disorders
Interventions
EPZ-5676
Drug
Lead sponsor
Epizyme, Inc.
Industry
Eligibility
18 Years to 90 Years
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
6
States / cities
Scottsdale, Arizona • Chicago, Illinois • New York, New York + 3 more
Source: ClinicalTrials.gov public record
Updated Mar 25, 2024 · Synced Sep 3, 2026, 6:41 AM EDT
Recruiting Phase 2 Interventional

A Study to Assess Adverse Events and Change in Disease Activity in Adult Participants Receiving Intravenously Infused Telisotuzumab Adizutecan Alone or With Standard of Care in Participants With Post Adjuvant Circulating Tumor DNA Positive Colorectal Cancer and No Radiographic Evidence of Disease

NCT07023289
View directory record Official record
Conditions
Colorectal Cancer
Interventions
Telisotuzumab Adizutecan, Standard of Care
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years and older
Enrollment
140 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
22
States / cities
Huntsville, Alabama • Fullerton, California • Los Angeles, California + 18 more
Source: ClinicalTrials.gov public record
Updated Jul 9, 2026 · Synced Sep 3, 2026, 6:41 AM EDT
Completed Not applicable Interventional Results available

Prevention of Intraoperative Nausea and Vomiting During Cesarean Section

NCT01216410
View directory record Official record
Conditions
Cesarean Delivery
Interventions
Metoclopramide, Phenylephrine infusion, Combination Group
Drug
Lead sponsor
Duke University
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
306 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Aug 5, 2014 · Synced Sep 3, 2026, 6:41 AM EDT
Recruiting Phase 4 Interventional

Post Operative Infusion Pump Pain Study

NCT07349810
View directory record Official record
Conditions
Post Operative Pain
Interventions
Bupivacaine 0.5% Injectable Solution, Ropivacaine 0.2% Injectable Solution, 1.3% liposomal bupivacaine (Exparel), ambIT Infusion Pump
Drug · Device
Lead sponsor
Rutgers, The State University of New Jersey
Other
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026
U.S. locations
1
States / cities
Somerset, New Jersey
Source: ClinicalTrials.gov public record
Updated Jan 20, 2026 · Synced Sep 3, 2026, 6:41 AM EDT
Recruiting No phase listed Observational

Lidocaine Infusion Treatment for Subarachnoid Hemorrhage Headaches

NCT06582810
View directory record Official record
Conditions
Subarachnoid; Hemorrhage, Nontraumatic, Headache
Interventions
Not listed
Lead sponsor
University of Kansas Medical Center
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
Wichita, Kansas
Source: ClinicalTrials.gov public record
Updated Jul 9, 2026 · Synced Sep 3, 2026, 6:41 AM EDT
Completed Phase 2 Interventional

Gemcitabine Alone or in Combination With Other Chemotherapy Drugs in Treating Patients With Metastatic Cancer of the Pancreas

NCT00012220
View directory record Official record
Conditions
Pancreatic Cancer
Interventions
cisplatin, docetaxel, gemcitabine hydrochloride, irinotecan hydrochloride
Drug
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older
Enrollment
259 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2009
U.S. locations
75
States / cities
Anniston, Alabama • La Jolla, California • San Diego, California + 55 more
Source: ClinicalTrials.gov public record
Updated Jul 13, 2016 · Synced Sep 3, 2026, 6:41 AM EDT
Completed Phase 2Phase 3 Interventional

Magnesium Chloride Versus Placebo in Patients Who Have Had a Stroke

NCT00933868
View directory record Official record
Conditions
Stroke
Interventions
Magnesium Chloride, Placebo
Drug
Lead sponsor
Relox Medical, LLC
Industry
Eligibility
18 Years to 90 Years
Enrollment
81 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
3
States / cities
Grand Rapids, Michigan • Suffern, New York • Toledo, Ohio
Source: ClinicalTrials.gov public record
Updated May 24, 2012 · Synced Sep 3, 2026, 6:41 AM EDT
Completed Not applicable Interventional

A Comparison of Air Insufflation, Water Immersion and Water Exchange Colonoscopy in Diagnostic Patients

NCT01781650
View directory record Official record
Conditions
Pain, Colorectal Adenomas, Colorectal Cancer
Interventions
Air Insufflation method., Water Immersion method., Water Exchange method.
Other
Lead sponsor
Presidio Ospedaliero Santa Barbara
Other
Eligibility
18 Years to 85 Years
Enrollment
288 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jan 14, 2014 · Synced Sep 3, 2026, 6:41 AM EDT
Recruiting Phase 1Phase 2 Interventional

Super-selective Intra-arterial Repeated Infusion of Cetuximab for the Treatment of Newly Diagnosed Glioblastoma

NCT02861898
View directory record Official record
Conditions
Glioblastoma, Brain Cancer, Brain Neoplasm, Brain Tumor, Brain Neoplasm, Malignant, EGFR Gene Overexpression, GBM
Interventions
Intra-arterial Cetuximab, Intra-arterial Mannitol
Drug
Lead sponsor
Northwell Health
Other
Eligibility
18 Years and older
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2029
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 31, 2026 · Synced Sep 3, 2026, 6:41 AM EDT
Completed Phase 1 Interventional

A Phase 1 Safety Study of SANGUINATE™ In Patients With Acute Severe Anemia.

NCT02754999
View directory record Official record
Conditions
Acute Anemia
Interventions
SANGUINATE™
Drug
Lead sponsor
Prolong Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
103 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
32
States / cities
Birmingham, Alabama • Prescott, Arizona • Baldwin Park, California + 26 more
Source: ClinicalTrials.gov public record
Updated Jun 26, 2017 · Synced Sep 3, 2026, 6:41 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Pharmacokinetics of Oral Mirabegron With Different Release Rates Versus Intravenous (IV) Mirabegron

NCT00940121
View directory record Official record
Conditions
Healthy, Pharmacokinetics of Mirabegron
Interventions
mirabegron
Drug
Lead sponsor
Astellas Pharma Inc
Industry
Eligibility
18 Years to 55 Years
Enrollment
91 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009
U.S. locations
1
States / cities
Tacoma, Washington
Source: ClinicalTrials.gov public record
Updated Oct 15, 2024 · Synced Sep 3, 2026, 6:41 AM EDT
Recruiting Phase 2 Interventional

PDS01ADC in Combination With Hepatic Artery Infusion Pump (HAIP) and Systemic Therapy for Subjects With Metastatic Colorectal Cancer, Intrahepatic Cholangiocarcinoma, or Metastatic Adrenocortical Carcinoma

NCT05286814
View directory record Official record
Conditions
Metastatic Colorectal Cancer (Mcrc), Intrahepatic Cholangiocarcinoma (Icc), Intrahepatic Bile Duct Cancer, Colorectal Neoplasms, Colorectal Cancer, Cholangiocarcinoma, Bile Duct Neoplasms, Bile Duct Cancer, Adrenocortical Carcinoma (ACC), Adrenal Cortical Carcinoma, Adrenal Gland Cancer, Adrenal Gland Neoplasms, Adrenal Cortex Neoplasms
Interventions
Dexamethasone, PDS01ADC, Intera 3000 Hepatic Artery Infusion Pump (HAIP), Floxuridine
Drug · Device
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 120 Years
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2028
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 1, 2026 · Synced Sep 3, 2026, 6:41 AM EDT
Completed Phase 1 Interventional

Super-Selective Intraarterial Intracranial Infusion of Avastin (Bevacizumab)

NCT00968240
View directory record Official record
Conditions
Glioblastoma Multiforme, Anaplastic Astrocytoma
Interventions
Super-Selective Intraarterial Intracranial Infusion of BEVACIZUMAB
Drug
Lead sponsor
Northwell Health
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 21, 2015 · Synced Sep 3, 2026, 6:41 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

CAR T Cell Receptor Immunotherapy Targeting VEGFR2 for Patients With Metastatic Cancer

NCT01218867
View directory record Official record
Conditions
Metastatic Cancer, Metastatic Melanoma, Renal Cancer
Interventions
Anti-VEGFR2 CAR CD8 plus PBL, Cyclophosphamide, Aldesleukin, Fludarabine
Biological · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 70 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 9, 2019 · Synced Sep 3, 2026, 6:41 AM EDT
Active, not recruiting Phase 2 Interventional

A Study to Investigate the Virologic Efficacy and Safety of VH3810109 + Cabotegravir Compared to Standard of Care (SOC) in Male and Female Adults Living With Human Immunodeficiency Virus (HIV)

NCT05996471
View directory record Official record
Conditions
HIV Infections
Interventions
VH3810109, Cabotegravir, Standard of care (SOC), rHuPH20
Biological · Drug
Lead sponsor
ViiV Healthcare
Industry
Eligibility
18 Years to 70 Years
Enrollment
185 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
43
States / cities
Birmingham, Alabama • Bakersfield, California • Los Angeles, California + 35 more
Source: ClinicalTrials.gov public record
Updated Jul 28, 2026 · Synced Sep 3, 2026, 6:41 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

Gene Therapy Using Anti-Her-2 Cells to Treat Metastatic Cancer

NCT00924287
View directory record Official record
Conditions
Metastatic Cancer
Interventions
in vitro tumor reactive, chimeric T cell receptor (CAR ) gene-transduced PBL plus IV aldesleukin, Cyclophosphamide, Fludarabine, Mesna
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 27, 2015 · Synced Sep 3, 2026, 6:41 AM EDT
Active, not recruiting Not applicable Interventional

Infusion System for Hepatic Cancer

NCT04684862
View directory record Official record
Conditions
Colorectal Cancer Metastatic to Liver, Intrahepatic Cholangiocarcinoma
Interventions
Medtronic SynchroMed II programmable pump connected to an Intera tapered catheter (Combined Infusion System)
Device
Lead sponsor
Ronald DeMatteo, M.D.
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2029
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 14, 2025 · Synced Sep 3, 2026, 6:41 AM EDT
Withdrawn Phase 3 Interventional

Aralast NP With Antiviral Treatment and Standard of Care Versus Antiviral Treatment With Standard of Care in Hospitalized Patients With Pneumonia and COVID-19 Infection

NCT04675086
View directory record Official record
Conditions
Covid19, Pneumonia, Viral
Interventions
alpha1-proteinase inhibitor, Antiviral Agents
Drug
Lead sponsor
Blessing Corporate Services, Inc
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021
U.S. locations
1
States / cities
Hannibal, Missouri
Source: ClinicalTrials.gov public record
Updated Dec 20, 2020 · Synced Sep 3, 2026, 6:41 AM EDT
Completed Phase 1 Interventional

Bone Marrow Stromal Cell Infusions for Stem Cell Transplant Complications

NCT01633229
View directory record Official record
Conditions
Graft-Versus-Host Disease
Interventions
Bone Marrow Stromal Cell Infusion
Procedure
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
18 Years to 75 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2018
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 11, 2019 · Synced Sep 3, 2026, 6:41 AM EDT